| Name | Title | Contact Details |
|---|
We`re building partnerships and transforming care. Alternate Solutions Health Network was founded in 1999 by David and Tessie Ganzsarto. We collaborate with health systems in joint venture partnerships to create a post-acute care solution, delivering efficient centralized operations and utilizing a best-in-class software platform. Our company has been dedicated, since the very beginning, to transforming the quality of care for both our partners and our patients. Our partnerships are built upon four cornerstones for maximizing quality outcomes and financial performance: Growth, Profitability, Quality Outcomes & Satisfaction, Compliance. By utilizing a centralized operational model we`re able to deliver the highest level of efficiency to our partners. Our model is uniquely suited for success in at-risk and value-based reimbursement models with payers, hospitals and other providers.
Zero Gravity Solutions is an agricultural biotechnology public company commercializing its technology derived from and designed for Space with significant applications on Earth. These technologies are focused on providing valuable solutions to challenges facing world agriculture. ZGSI’s two primary categories of technologies aimed at sustainable agriculture are: 1) BAM-FX™ technology, a cost effective, ionic micronutrient delivery system for plants currently being introduced commercially into world agriculture by Zero Gravity’s wholly owned subsidiary BAM Agricultural Solutions and 2) Directed Selection™, utilized in the development and production, in the prolonged zero/micro gravity environment of the International Space Station, of large volumes of non-GMO, novel, patentable stem cells with unique and beneficial characteristics.
Global BioChem is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases. -We seek technologies or targets designed to predict, preempt or intervene before immune disease begins, re-appears or progresses. -We are creating a new biopharmaceutical category for autoimmunity. We leverage a transformational drug development strategy that sources, repositions and advances candidates that: -Target the interception or prevention of immune-mediated disease -Have been underdeveloped or deprioritized because of insufficient clinical trial efficacy or for strategic reasons -Have demonstrated proof-of-mechanism by preventing or intercepting immunopathologic pathways We believe that our deep understanding of immune-mediated pathophysiology, experience in translational medicine, and expertise in the design of rapid go/no-go clinical trials enables us to identify and evaluate potential therapeutic candidates for acquisition or in-licensing.
Arresto BioSciences is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.